Researchers from the US recently reported the preclinical development of a self-amplifying mRNA (SAM) vaccine that encodes a prefusion-stabilized SARS-CoV-2 spike glycoprotein.
Researchers from the US recently reported the preclinical development of a self-amplifying mRNA (SAM) vaccine that encodes a prefusion-stabilized SARS-CoV-2 spike glycoprotein.